Randomized Trialhigh evidence
Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial.
European heart journal·August 31, 2026·PMID 42670194
Why it mattersMany high-risk ASCVD patients fail to reach LDL-C targets despite statins and ezetimibe. This head-to-head trial provides direct evidence that inclisiran achieves substantially greater LDL-C lowering and goal attainment than bempedoic acid, informing add-on therapy selection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled